{
    "eid": "2-s2.0-85146364976",
    "title": "Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Na\u00efve Patients with ALK+ Non-Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        },
        {
            "@_fa": "true",
            "$": "Cancer Research",
            "@code": "1306",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "ALK-activated",
        "ALK-inhibitors",
        "Ceritinib",
        "Non-small-cell lung carcinoma"
    ],
    "authors": [
        "Byoung Chul Cho",
        "Dong Wan Kim",
        "Ullas Batra",
        "Keunchil Park",
        "Sang We Kim",
        "Cheng Ta Yang",
        "Pei Jye Voon",
        "Virote Sriuranpong",
        "K. Govind Babu",
        "Khalid Amin",
        "Yingbo Wang",
        "Paramita Sen",
        "Khemaies Slimane",
        "Sarayut Geater"
    ],
    "citedby-count": 0,
    "ref-count": 25,
    "ref-list": [
        "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer",
        "First-line crizotinib versus chemotherapy in ALK-positive lung cancer",
        "First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study",
        "The emerging therapeutic landscape of ALK inhibitors in non-small cell lung cancer",
        "Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial",
        "Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2",
        "Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial",
        "ASCEND-8: a randomized phase 1 study of ceritinib, 450 mg or 600 mg, taken with a low-fat meal versus 750 mg in fasted state in patients with snaplastic lymphoma kinase (ALK)-rearranged metastatic non-small cell lung cancer (NSCLC)",
        "Efficacy and safety of ceritinib (450 mg/d or 600 mg/d) with food versus 750-mg/d fasted in patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC: primary efficacy results from the ASCEND-8 study",
        "Ceri-tinib efficacy and safety in treatment-naive Asian patients with advanced ALK-rearranged NSCLC: an ASCEND-4 subgroup analysis",
        "Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study",
        "Alectinib (ALC) vs crizotinib (CRZ) in treatment-na\u00efve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study",
        "Crizotinib versus chemotherapy in Asian patients with ALK-positive advanced non-small cell lung cancer",
        "Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer",
        "Updated overall survival and final progresReferences sion-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study",
        "Cost effectiveness of ceritinib and alectinib versus crizotinib in first-line anaplastic lymphoma kinasepositive advanced non-small-cell lung cancer",
        "The central nervous system as a sanctuary site in ALK-positive nonsmall-cell lung cancer",
        "Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases",
        "Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group",
        "Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors",
        "Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases",
        "Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain"
    ],
    "affiliation": [
        {
            "affiliation-city": "Basel",
            "@id": "60009968",
            "affilname": "Novartis International AG",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60009968",
            "affiliation-country": "Switzerland"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60115402",
            "affilname": "Yonsei Cancer Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60115402",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Kuching",
            "@id": "60090650",
            "affilname": "Hospital Umum Sarawak",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60090650",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "New Delhi",
            "@id": "60070271",
            "affilname": "Rajiv Gandhi Cancer Institute and Research Centre",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60070271",
            "affiliation-country": "India"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60068691",
            "affilname": "Asan Medical Center",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60068691",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60021119",
            "affilname": "Seoul National University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021119",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60020857",
            "affilname": "Samsung Medical Center, Sungkyunkwan university",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020857",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Taoyuan",
            "@id": "60020351",
            "affilname": "Chang Gung University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020351",
            "affiliation-country": "Taiwan"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bengaluru",
            "@id": "60003789",
            "affilname": "Kidwai Memorial Institute of Oncology India",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60003789",
            "affiliation-country": "India"
        }
    ],
    "funding": [
        "Novartis Healthcare Pvt Ltd.",
        "Novartis Pharmaceuticals Corporation"
    ]
}